Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Simiao Yongan Decoction is a traditional Chinese medicine (TCM) herbal formula derived from the classic Simiao Yongan Decoction, which traditionally consists of Lonicera japonica (honeysuckle), Scrophularia ningpoensis (figwort), Angelica sinensis (Chinese angelica), and Glycyrrhiza uralensis (licorice). The modified formulation is being evaluated by the Chengdu University of Traditional Chinese Medicine for the treatment of diabetic foot ulcers (DFUs), particularly in patients presenting with damp-heat toxins accumulation syndrome. It is administered orally as a decoction, often in combination with standard endovascular therapy and wound care. The therapeutic mechanism of Modified Simiao Yongan Decoction involves promoting wound healing, improving peripheral nerve damage, enhancing angiogenesis, and regulating inflammation and oxidative stress, potentially through pathways such as METTL14/BECN1 and NLRP3 inflammasome inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Simiao Yongan decoction.